Commentary

What happens when newer weight loss meds are stopped?


 

Social media outlets are full of stories about celebrities who have lost weight with the new generation of incretin medications like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro).

Some of these medicines are approved for treating obesity (Wegovy), whereas others are approved for type 2 diabetes (Ozempic and Mounjaro). Tirzepatide (Mounjaro) has been fast-tracked for approval for weight loss by the U.S. Food and Drug Administration this year, and in the first of the series of studies looking at its effect on obesity, the SURMOUNT-1 trial, tirzepatide demonstrated a mean weight loss of around 22% in people without diabetes, spurring significant off-label use.

Our offices are full of patients who have taken these medications, with unprecedented improvements in their weight, cardiometabolic health, and quality of life. What happens when patients stop taking these medications? Or more importantly, why stop them?

Although these drugs are very effective for weight loss and treating diabetes, there can be adverse effects, primarily gastrointestinal, that limit treatment continuation. Nausea is the most common side effect and usually diminishes over time. Slow dose titration and dietary modification can minimize unwanted gastrointestinal side effects.

Drug-induced acute pancreatitis, a rare adverse event requiring patients to stop therapy, was seen in approximately 0.2% of people in clinical trials.

Medications effective but cost prohibitive?

Beyond adverse effects, patients may be forced to stop treatment because of medication cost, changes in insurance coverage, or issues with drug availability.

Two incretin therapies currently approved for treating obesity – liraglutide (Saxenda) and semaglutide (Wegovy) – cost around $1,400 per month. Insurance coverage and manufacturer discounts can make treatment affordable, but anti-obesity medicines aren’t covered by Medicare or by many employer-sponsored commercial plans.

Changes in employment or insurance coverage, or expiration of manufacturer copay cards, may require patients to stop or change therapies. The increased prescribing and overall expense of these drugs have prompted insurance plans and self-insured groups to consider whether providing coverage for these medications is sustainable.

Limited coverage has led to significant off-label prescribing of incretin therapies that aren’t approved for treating obesity (for instance, Ozempic and Mounjaro) and compounding pharmacies selling peptides that allegedly contain the active pharmaceutical ingredients. High demand for these medications has created significant supply shortages over the past year, causing many people to be without treatment for significant periods of time, as reported by this news organization.

Recently, I saw a patient who lost more than 30 pounds with semaglutide (Wegovy). She then changed employers and the medication was no longer covered. She gained back almost 10 pounds over 3 months and was prescribed tirzepatide (Mounjaro) off-label for weight loss by another provider, using a manufacturer discount card to make the medication affordable. The patient did well with the new regimen and lost about 20 pounds, but the pharmacy stopped filling the prescription when changes were made to the discount card. Afraid of regaining the weight, she came to see us as a new patient to discuss her options with her lack of coverage for anti-obesity medications.

Pages

Recommended Reading

Causal link found between childhood obesity and adult-onset diabetes
MDedge Internal Medicine
What’s it like to take Ozempic? A doctor’s own story
MDedge Internal Medicine
Treat together: Tackle heart disease and obesity simultaneously
MDedge Internal Medicine
Factors linked with increased VTE risk in COVID outpatients
MDedge Internal Medicine
High caffeine levels may lower body fat, type 2 diabetes risks
MDedge Internal Medicine
TikTok’s fave weight loss drugs: Link to thyroid cancer?
MDedge Internal Medicine
Ozempic: The latest weight loss craze and how over-prescribing is harming patients
MDedge Internal Medicine
Mediterranean diet linked to 24% reduction in CVD risk in women
MDedge Internal Medicine
What’s the ‘secret sauce’ to help patients move more?
MDedge Internal Medicine
Should GI own the obesity field?
MDedge Internal Medicine